02 September 2024: Articles
Statin-Induced Autoimmune Myopathy: A Diagnostic Challenge in Muscle Weakness
Challenging differential diagnosis, Diagnostic / therapeutic accidents, Unusual setting of medical care, Rare disease, Adverse events of drug therapy
Maryam Barkhordarian 1ABEF*, Mark Grijalva1EF, Albert Lee1AE, Amer Jarri1ABE, Anna Belyayeva1BCDF, Simcha Weissman1DEFDOI: 10.12659/AJCR.944261
Am J Case Rep 2024; 25:e944261
Abstract
BACKGROUND: Statin-induced myopathy can present with symptoms ranging from mild myalgia to significant muscle weakness. Muscle-related adverse effects of statins have been very challenging in clinical practice and they necessitate high clinical suspicion. This case report highlights how statin-induced autoimmune myopathy often goes undiagnosed.
CASE REPORT: We present a 69-year-old man with a past medical history of coronary artery disease who presented with myalgia and progressive proximal muscle weakness for 2 months, with a creatinine kinase of 8323 U/L. Atorvastatin was held on admission and the patient received intravenous (IV) fluid as treatment for presumed rhabdomyolysis. Although CK was trending down, he did not show significant improvement in muscle weakness or myalgia. At this point, myositis was suspected, so a myositis panel including anti-HMG Co-A reductase antibody was ordered and he was started on IV steroids. Anti-HMG Co-A reductase antibody was positive, and the rest of myopathy workup was negative. Meanwhile, the patient’s muscle weakness significantly improved with IV steroid. He was discharged on methylprednisolone with close outpatient rheumatology follow-up.
CONCLUSIONS: Muscle-related adverse effects of statins, including rhabdomyolysis and myopathy, can fail to respond to conservative management. It is crucial to identify and manage statin-induced autoimmune myopathy as a possible differential diagnosis in patients with muscle weakness and elevated CK while on statin therapy who do not respond to intravenous fluid alone.
Keywords: atorvastatin, Muscle Weakness, myositis, Rhabdomyolysis, Cerivastatin-Induced
Introduction
Statin-class medications are some of the most prescribed medications as they contribute to reduction in low-density lipoprotein cholesterol (LDL-C) via inhibition of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase and improve atherosclerotic cardiovascular disease (ASCVD) scores [1]. Approximately 28% of adults age 40 and over are using a statin-class medication, with approximately 78 million US adults estimated to be on this medication [2,3]. The adverse effects profile of this class of medications is well known and muscle adverse-effects range from benign myalgia and myopathy without creatinine kinase (CK) elevation to severe drug-induced myopathy. The prevalence of benign clinical myopathy without evidence of CK increase is estimated to be approximately 10–25%, and it often leads to discontinuation of and aversion to this class of medication [4,5]. However, the incidence of drug-related clinically significant myonecrosis and rhabdomyolysis is less than 0.1% [5]. Here, we present a case report illustrating how statin-induced autoimmune myopathy often remains undiagnosed.
Case Report
A 69-year-old man with a past medical history of coronary artery disease, hypertension, hyperlipidemia, type 2 diabetes mellitus, and heart failure presented to the Emergency Department with muscle weakness and myalgias. About 2 months prior to admission, he began experiencing weakness with activity, which gradually worsened over time. He also reported cramping in the upper and lower extremities. He had been taking atorvastatin 80 mg once nightly for 5 years. Other home medications included carvedilol, sacubitril-valsartan, tamsulosin, finasteride, and aspirin, but no agents that can cause myopathy.
His physical exam was notable for significant weakness in bilateral proximal upper and lower extremities. On laboratory investigation, the patient had controlled diabetes with hemoglobin A1c of 5.3% and creatinine kinase at 8323U/L (reference range, 44–196 U/L). No renal insufficiency or myoglobinuria were noted. In light of the patient’s long history of statin usage, myalgias with muscle weakness, elevated creatinine kinase, and abnormal urinalysis, myopathy secondary to statin use was considered. Atorvastatin was held and the patient received intravenous (IV) fluid for management of rhabdomyolysis. His hospital course was complicated with respiratory failure necessitating intubation secondary to volume overload for a presumed rhabdomyolysis, despite careful monitoring with auscultation and oxygen saturation. He received 4200 cc total intravenous fluid since admission, and prior to intubation had an overall net negative balance. Given the respiratory failure in the setting of volume overload, acute decompensated heart failure was suspected, and the initial echocardiogram reflected heart failure with reduced ejection fraction of 40–45%. He also underwent cardiac catheterization to exclude any ischemic cause of heart failure.
Although the CK trended down to 3248 U/L, there was no significant improvement in muscular symptoms. At this point, given the patient’s muscle weakness and elevated CK, myositis was suspected. A myositis panel including anti-HMG Co-A reductase antibody was ordered and the patient was started on IV methylprednisolone. Anti-HMG Co-A reductase antibody was positive and the rest of myopathy workup was negative and there was no positive antibody against collagen disease. His muscle weakness significantly improved with IV methylprednisolone 40 mg every 8 hours during hospitalization. He was discharged with 60 mg of oral prednisone. On outpatient rheumatology follow-up, given incomplete improvement in myalgia and muscle weakness after 2 months of prednisone 60 mg, the steroid dose was tapered weekly and intravenous immunoglobulin (IVIG) 50 g every 4 weeks for 3 months was initiated. After 3 months of treatment with IVIG and tapering of prednisone, he regained his strength, and the CK level normalized to 28 U/L. A Figure 1 shows his clinical progress.
Discussion
Rhabdomyolysis can occur due to trauma or metabolic and exertional causes. It is important to find the cause and treat accordingly to prevent complications such as acute kidney injury [6]. Drug-induced rhabdomyolysis has been associated with multiple medications such as leflunomide, trabectedin, propofol, and daptomycin [7]. There are a few case reports of diphenhydramine, ecstasy, and baclofen inducing rhabdomyolysis in the pediatric population [8]. Statins can have adverse effects on muscles, including myalgia, myositis, and rhabdomyolysis, which can present with muscle pain, weakness, elevated creatinine kinase, myoglobinuria, and renal failure [9].
In our case, statin use induced rhabdomyolysis, which did not respond to the usual treatment of holding the inductive medication and administering intravenous fluid. Further investigation detected anti-HMGCR antibody and diagnosis of autoimmune myopathy. Statin-induced myopathy can be self-limited non-immune-mediated, which gradually improves after discontinuation of statin. However, immune-mediated myopathy caused by anti-HMGCR antibodies usually requires an immunosuppressant [10]. In a retrospective study in Lahore, about 50% of patients treated with statins had myalgia [11]. The incidence of statin-induced myopathy was reported at 11 cases in 100000 patients and the incidence of rhabdomyolysis caused by statins was reported to be about 4–7 in 100 000 cases [12]. The incidence of statin-associated autoimmune myopathy is estimated at 2–3 new cases per 100 000 patients [13]. Although rare, this etiology must be considered when muscle weakness or pain presents with elevations in CK ranging from 10x to 40x the upper limit of normal, defining myopathy and rhabdomyolysis, respectively [14]. However, the coincidence of autoimmune myopathy secondary to anti-HMG CoA reductase with other autoimmune disorders is not clear. A study of 82 participants with idiopathic inflammatory myopathy (IIM) reported that the prevalence of anti-HMG CoA reductase in these patients was unusually high [15]. It is crucial to have a clinical suspicion of this diagnosis in mind when the originally diagnosed disease is not responding to treatment, as it may not be as rare as thought, but rather may be widely undiagnosed. In patients not responding to statin withdrawal, the general approach is use of immunosuppressants such as steroids and intravenous immunoglobulins [16]. However, use of mycophenolate and tacrolimus in addition to steroids was also reported to be helpful [17,18].
Conclusions
In our case report, we highlighted the importance of evaluating anti-HMGCR antibodies in patients without adequate response to conservative therapy, including withdrawal of statins, and IV fluid therapy in the setting of rhabdomyolysis and renal injury. It is important to notice that the rarity of this phenomenon may not be due to low incidence but rather due to inadequate clinical suspicion for diagnosis and treatment of this condition.
References:
1.. Arnett DK, Blumenthal RS, Albert MA, 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: J Am Coll Cardiol, 2019; 74(10); 1376-414
2.. Diana Hla RJ, Roger S, Blumenthal, Seth Shay Martin: Assessing severity of statin side effects: Fact versus fiction, 2018, American College of Cardiology 04/09/2018:
3.. Gu Q, Paulose-Ram R, Burt VL, Kit BK, Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003–2012: NCHS Data Brief, 2014(177); 1-8
4.. Ganga HV, Slim HB, Thompson PD, A systematic review of statin-induced muscle problems in clinical trials: Am Heart J, 2014; 168(1); 6-15
5.. Mefford MT, Tajeu GS, Tanner RM, Willingness to be reinitiated on a statin (from the REasons for Geographic and Racial Differences in Stroke Study): Am J Cardiol, 2018; 122(5); 768-74
6.. Prendergast BD, George CF, Drug-induced rhabdomyolysis – mechanisms and management: Postgrad Med J, 1993; 69(811); 333-36
7.. Hohenegger M, Drug induced rhabdomyolysis: Curr Opin Pharmacol, 2012; 12(3); 335-39
8.. Coco TJ, Klasner AE, Drug-induced rhabdomyolysis: Curr Opin Pediatr, 2004; 16(2); 206-10
9.. Abd TT, Jacobson TA, Statin-induced myopathy: A review and update: Expert Opin Drug Saf, 2011; 10(3); 373-87
10.. Selva-O’Callaghan A, Alvarado-Cardenas M, Pinal-Fernández I, Statin-induced myalgia and myositis: An update on pathogenesis and clinical recommendations: Expert Rev Clin Immunol, 2018; 14(3); 215-24
11.. Sadeeqa S, Maqsood M, Ahmad M, Prevalence of statin induced myopathy in Lahore, Pakistan: Pak J Pharm Sci, 2018; 31(2(Suppl.)); 617-22
12.. Law M, Rudnicka AR, Statin safety: A systematic review: Am J Cardiol, 2006; 97(8a); 52c-60c
13.. Mammen AL, Statin-asssociated autoimmune myopathy: N Engl J Med, 2016; 374(7); 664-69
14.. Newman CB, Preiss D, Tobert JA, Statin safety and associated adverse events: A scientific statement from the American Heart Association: Arterioscler Thromb Vasc Biol, 2019; 39(2); e38-e81
15.. Douglass-Molloy H, Limaye V, Prevalence of polymyalgia rheumatica in a cohort of patients with idiopathic inflammatory myopathy: Clin Rheumatol, 2020; 39(4); 1217-21
16.. Ramanathan S, Langguth D, Hardy TA, Clinical course and treatment of anti-HMGCR antibody-associated necrotizing autoimmune myopathy: Neurol Neuroimmunol Neuroinflamm, 2015; 2(3); e96
17.. Akivis Y, Kurup M, John S, Statin-induced necrotizing autoimmune myositis: J Med Cases, 2022; 13(10); 513-16
18.. Cha D, Wang F, Mukerji B, Mukerji V, Statin-induced necrotizing autoimmune myositis: Diagnosis and management: Cureus, 2021; 13(3); e13787
In Press
Case report
Dynamic Ultrasound Assessment of Celiac Artery Flow Velocity in Median Arcuate Ligament Syndrome DiagnosisAm J Case Rep In Press; DOI: 10.12659/AJCR.945253
Case report
Recurrent Heterotopic Pregnancy Following Frozen-Thawed Embryo Transfer: A Case Study and Comprehensive Lit...Am J Case Rep In Press; DOI: 10.12659/AJCR.945053
Case report
Iron-Related Pseudomelanosis Duodeni in a Patient with Gastrointestinal Bleeding: A Case ReportAm J Case Rep In Press; DOI: 10.12659/AJCR.945238
Case report
Aortic Homografts in Surgical Management of Prosthetic Valve Endocarditis: A Case Series from GreeceAm J Case Rep In Press; DOI: 10.12659/AJCR.945030
Most Viewed Current Articles
21 Jun 2024 : Case report 57,564
Intracranial Parasitic Fetus in a Living Infant: A Case Study with Surgical Intervention and Prognosis Anal...DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report 42,502
Neurocysticercosis Presenting as Migraine in the United StatesDOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133
10 Jan 2022 : Case report 32,442
A Report on the First 7 Sequential Patients Treated Within the C-Reactive Protein Apheresis in COVID (CACOV...DOI :10.12659/AJCR.935263
Am J Case Rep 2022; 23:e935263
23 Feb 2022 : Case report 19,925
Penile Necrosis Associated with Local Intravenous Injection of CocaineDOI :10.12659/AJCR.935250
Am J Case Rep 2022; 23:e935250